Urothelial Cancer Clinical Trials in Portland, Oregon

4 studies are recruiting for urothelial cancer in Portland, Oregon right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

    This is a global, multicenter, randomized, open-label, Phase 2/3 study of Dato-DXd plus carboplatin or cisplatin versus gemcitabine plus carboplatin or cisplatin in participants with la/mUC who progressed during or after EV plus pembrolizumab combination treatment. This trial will start with part A…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Research Site, Portland, Oregon
    Locations
    100 in total
    Run by
    Daiichi Sankyo

    See if you can join NCT07129993 on ClinicalTrials.gov

  2. Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

    This study is being done to learn more about a new medicine called PF-08634404. It is for adults with a type of bladder cancer called locally advanced or metastatic urothelial cancer (LA/mUC), meaning the cancer has spread to nearby tissues or other parts of the body. The purpose of the study is to…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Northwest Cancer Specialists, P.C., Portland, Oregon
    Locations
    153 in total
    Run by
    Pfizer

    See if you can join NCT07421700 on ClinicalTrials.gov

  3. Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

    TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.

    Stage
    Phase 2
    Ages
    18 to 130
    Site
    Research Site, Portland, Oregon
    Locations
    96 in total
    Run by
    AstraZeneca

    See if you can join NCT05489211 on ClinicalTrials.gov

  4. Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

    A Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or After Immunotherapy

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Local Institution - 0141, Portland, Oregon
    Locations
    163 in total
    Run by
    Bristol-Myers Squibb

    See if you can join NCT07106762 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.